The DOI matches its Crossref record.
β-cells in type II diabetes mellitus
Abstract
In 1960, immunoassays of insulin first demonstrated significant quantities of circulating hormone in non-insulin-dependent (type II) diabetes and for 30 yr have fostered debate as to whether a β-cell abnormality plays an etiological role in this syndrome. Early efforts to determine the adequacy of islet β-cell function showed that obesity and its associated insulin resistance were major confounding variables. Subsequently, it was recognized that glucose not only directly regulated insulin synthesis and secretion but moderated all other islet signals, including other substrates, hormones, and neural factors. When both obesity and glucose are taken into account, it becomes clear that patients with fasting hyperglycemia all have abnormal islet function. Type II diabetes is characterized by a defect in first-phase or acute glucose-induced insulin secretion and a deficiency in the ability of glucose to potentiate other islet nonglucose β-cell secretagogues. The resulting hyperglycemia compensates for the defective glucose potentiation and maintains nearly normal basal insulin levels and insulin responses to nonglucose secretagogues but does not correct the defect in first-phase glucose-induced insulin release. Before the development of fasting hyperglycemia, only first-phase glucose-induced insulin secretion is obviously defective. This is because progressive islet failure is matched by rising glucose levels to maintain basal and second-phase insulin output. The relationship between islet function and fasting plasma glucose is steeply curvilinear, so that there is a 75% loss of β-cell function by the time the diagnostic level of 140 mg/dl is exceeded. This new steady state is characterized by glucose overproduction and inefficient utilization. Insulin resistance is also present in most patients and contributes to the hyperglycemia by augmenting the glucose levels needed for compensation. Decompensation and absolute hypoinsulinemia occur when the renal threshold for glucose is exceeded and prevents further elevation of circulating glucose. The etiology of the islet β-cell lesion is not known, but a hypothesis based on basal hyperproinsulinemia and islet amyloid deposits in the pancreas of type II diabetes is reviewed. The recent discovery of the islet amyloid polypeptide (IAPP) or amylin, which is the major constituent of islet amyloid deposits, is integrated into this hypothesis. It is suggested that pro-IAPP and proinsulin processing and mature peptide secretion normally occur together and that abnormal processing, secondary to or in conjunction with defects in hormone secretion, lead to progressive accumulation of intracellular IAPP and pro-IAPP, which in cats, monkeys, and humans form intracellular fibrils and amyloid deposits with a loss of β-cell mass. This process is accelerated by increased β-cell demand from insulin resistance. Thus, type II diabetes is reviewed as a heterogenous disorder in which islet dysfunction plays a critical role. Insulin resistance interacts to produce the final syndrome, in which deposition of pancreatic islet amyloid is probably an important long-term contributor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
Dietary Fiber, Glycemic Load, and Risk of Non—insulin-dependent Diabetes Mellitus in Women
Salmerón, J. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540300040031 · Cited by 1,804
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
The Role for Endoplasmic Reticulum Stress in Diabetes Mellitus
Eizirik, D. L., Cardozo, A. K., & Cnop, M. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0015 · Cited by 1,173
Kulkarni, R. N., Brüning, J. C., Winnay, J. N., Postic, C., Magnuson, M. A., & Kahn, C. R. (1999) · Cell · doi:10.1016/s0092-8674(00)80546-2 · Cited by 1,148
Five stages of evolving beta-cell dysfunction during progression to diabetes
Weir, G. C., & Bonner-Weir, S. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s16 · Cited by 1,126
Mechanism linking diabetes mellitus and obesity
Algoblan, A., Alalfi, M., & Khan, M. (2014) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s67400 · Cited by 1,028
New drug targets for type 2 diabetes and the metabolic syndrome
Moller, D. E. (2001) · Nature · doi:10.1038/414821a · Cited by 1,008
Health implications of obesity
Pi-Sunyer, F. (1991) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/53.6.1595s · Cited by 809
Naggert, J. K., Fricker, L. D., Varlamov, O., Nishina, P. M., Rouille, Y., Steiner, D. F., Carroll, R. J., Paigen, B. J., & Leiter, E. H. (1995) · Nature Genetics · doi:10.1038/ng0695-135 · Cited by 663
The Importance of β-Cell Failure in the Development and Progression of Type 2 Diabetes
Kahn, S. E. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7713 · Cited by 660
Free Fatty Acids and Pathogenesis of Type 2 Diabetes Mellitus
BERGMAN, R., & ADER, M. (2000) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(00)00323-4 · Cited by 622
(2000) · Medicine & Science in Sports & Exercise · doi:10.1097/00005768-200007000-00024 · Cited by 604
Chang, A. M., & Halter, J. B. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00366.2002 · Cited by 585
The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Tuomi, T., Groop, L. C., Zimmet, P. Z., Rowley, M. J., Knowles, W., & Mackay, I. R. (1993) · Diabetes · doi:10.2337/diab.42.2.359 · Cited by 581
Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1133 · Cited by 540
Laferrère, B., Heshka, S., Wang, K., Khan, Y., McGinty, J., Teixeira, J., Hart, A. B., & Olivan, B. (2007) · Diabetes Care · doi:10.2337/dc06-1549 · Cited by 532
Type 2 Diabetes in the Young: The Evolving Epidemic
Alberti, G., Zimmet, P., Shaw, J., Bloomgarden, Z., Kaufman, F., Silink, M., & for the Consensus Workshop Group (2004) · Diabetes Care · doi:10.2337/diacare.27.7.1798 · Cited by 493
Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454
AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome
Ruderman, N., & Prentki, M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1344 · Cited by 451
Mu, J., Woods, J., Zhou, Y.-P., Roy, R. S., Li, Z., Zycband, E., Feng, Y., Zhu, L., Li, C., Howard, A. D., et al. (2006) · Diabetes · doi:10.2337/db05-1602 · Cited by 449
Malonyl-CoA Signaling, Lipid Partitioning, and Glucolipotoxicity
Prentki, M., Joly, E., El-Assaad, W., & Roduit, R. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s405 · Cited by 431
Degn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427
Gerich, J. E. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.4.0338 · Cited by 420
Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414
Nishikawa, T., & Araki, E. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.1458 · Cited by 391
Wang, Z., & Thurmond, D. C. (2009) · Journal of Cell Science · doi:10.1242/jcs.034355 · Cited by 386
Dunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369
Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy.
Rizza, R. A. (2010) · Diabetes · doi:10.2337/db10-1032 · Cited by 367
Seghers, V., Nakazaki, M., DeMayo, F., Aguilar-Bryan, L., & Bryan, J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.13.9270 · Cited by 365
The Cellular Fate of Glucose and Its Relevance in Type 2 Diabetes
Bouché, C., Serdy, S., Kahn, C. R., & Goldfine, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0026 · Cited by 346
Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids.
Delaunay, F., Khan, A., Cintra, A., Davani, B., Ling, Z. C., Andersson, A., Ostenson, C. G., Gustafsson, J., Efendic, S., & Okret, S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119743 · Cited by 333
Bloomgarden, Z. T. (2004) · Diabetes Care · doi:10.2337/diacare.27.4.998 · Cited by 325
Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes
Fukushima, M., Suzuki, H., & Seino, Y. (2004) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2003.11.024 · Cited by 313
Jensen, C. C., Cnop, M., Hull, R. L., Fujimoto, W. Y., Kahn, S. E., & the American Diabetes Association GENNID Study Group (2002) · Diabetes · doi:10.2337/diabetes.51.7.2170 · Cited by 312
Methods for clinical assessment of insulin sensitivity and β-cell function
Pacini, G., & Mari, A. (2003) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/s1521-690x(03)00042-3 · Cited by 308
Vaag, A., Henriksen, J. E., & Beck-Nielsen, H. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115656 · Cited by 299
Canine and Feline Diabetes Mellitus: Nature or Nurture?
Rand, J. S., Fleeman, L. M., Farrow, H. A., Appleton, D. J., & Lederer, R. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.8.2072s · Cited by 287
Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
Holst, J. J., Knop, F. K., Vilsbøll, T., Krarup, T., & Madsbad, S. (2011) · Diabetes Care · doi:10.2337/dc11-s227 · Cited by 280
Carbohydrate Metabolism in Non-Insulin-Dependent Diabetes Mellitus
Dinneen, S., Gerich, J., & Rizza, R. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271007 · Cited by 279
Verchere, C. B., D'Alessio, D. A., Palmiter, R. D., Weir, G. C., Bonner-Weir, S., Baskin, D. G., & Kahn, S. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3492 · Cited by 278
Expression of adiponectin receptors in pancreatic β cells
Kharroubi, I., Rasschaert, J., Eizirik, D. L., & Cnop, M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.11.042 · Cited by 270
Genetic and environmental determinants of non‐insulin‐dependent diabetes mellitus (NIDDM)
Hamman, R. F. (1992) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610080402 · Cited by 256
Greenfield, J. R., Farooqi, I. S., Keogh, J. M., Henning, E., Habib, A. M., Blackwood, A., Reimann, F., Holst, J. J., & Gribble, F. M. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26362 · Cited by 256
Fatty acid metabolism and insulin secretion in pancreatic beta cells
Yaney, G. C., & Corkey, B. E. (2003) · Diabetologia · doi:10.1007/s00125-003-1207-4 · Cited by 255
Bojsen-Møller, K. N., Dirksen, C., Jørgensen, N. B., Jacobsen, S. H., Serup, A. K., Albers, P. H., Hansen, D. L., Worm, D., Naver, L., Kristiansen, V. B., et al. (2014) · Diabetes · doi:10.2337/db13-1307 · Cited by 254
Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation
Carpentier, A., Mittelman, S. D., Lamarche, B., Bergman, R. N., Giacca, A., & Lewis, G. F. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.276.6.e1055 · Cited by 254
Gerich, J. E. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.4.447 · Cited by 222
Cavaghan, M. K., Ehrmann, D. A., Byrne, M. M., & Polonsky, K. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119562 · Cited by 216
Vaag, A., Henriksen, J. E., Madsbad, S., Holm, N., & Beck-Nielsen, H. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117715 · Cited by 206
Type 2 Diabetes Mellitus and Skeletal Muscle Metabolic Function
Phielix, E., & Mensink, M. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2008.01.020 · Cited by 198
The Importance of Hyperglycemia in the Nonfasting State to the Development of Cardiovascular Disease
Haffner, S. M. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0343 · Cited by 193
“The presence of these products is probably a marker of loss of b-cell function (65), and elevated proinsulin levels are also associated with increased cardiovascular risk factors (63, 66, 67).”
BackgroundGheni, G., Ogura, M., Iwasaki, M., Yokoi, N., Minami, K., Nakayama, Y., Harada, K., Hastoy, B., Wu, X., Takahashi, H., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.09.030 · Cited by 156
Limesand, S. W., Jensen, J., Hutton, J. C., & Hay, W. W. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00494.2004 · Cited by 153
Dietary carbohydrates and insulin action in humans
Wolever, T. M. S. (2000) · British Journal of Nutrition · doi:10.1017/s0007114500001021 · Cited by 127
Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents?
Stern, M. P. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-1_part_2-199601011-00006 · Cited by 115
Alford, F., Beck-Nielsen, H., Ward, G. M., & Henriksen, J. E. (1997) · Diabetologia · doi:10.1007/s001250050847 · Cited by 115
Impaired glucose homeostasis in insulin-like growth factor binding protein-1 transgenic mice
Rajkumar, K., Krsek, M., Dheen, S. T., & Murphy, L. J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118982 · Cited by 97
Ikenoue, T., Akiyoshi, M., Fujitani, S., Okazaki, K., Kondo, N., & Maki, T. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0700875 · Cited by 93
“This particularly involves postprandial insulin secretion (Polonsky et al., 1988; Porte, 1991).”
BackgroundOverweight in adult cats: a cross-sectional study
Öhlund, M., Palmgren, M., & Holst, B. S. (2018) · Acta Veterinaria Scandinavica · doi:10.1186/s13028-018-0359-7 · Cited by 91
Højberg, P. V., Zander, M., Vilsbøll, T., Knop, F. K., Krarup, T., Vølund, A., Holst, J. J., & Madsbad, S. (2008) · Diabetologia · doi:10.1007/s00125-008-0943-x · Cited by 89
Identification of Differential Responses to an Oral Glucose Tolerance Test in Healthy Adults
Morris, C., O’Grada, C., Ryan, M., Roche, H. M., Gibney, M. J., Gibney, E. R., & Brennan, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072890 · Cited by 88
Mohan, V., Amutha, A., Ranjani, H., Unnikrishnan, R., Datta, M., Anjana, R. M., Staimez, L., Ali, M. K., & Narayan, K. M. V. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0259 · Cited by 82
Kahn, S. E., Verchere, C. B., Andrikopoulos, S., Asberry, P. J., Leonetti, D. L., Wahl, P. W., Boyko, E. J., Schwartz, R. S., Newell-Morris, L., & Fujimoto, W. Y. (1998) · Diabetes · doi:10.2337/diabetes.47.4.640 · Cited by 74
Malmgren, S., Spégel, P., Danielsson, A. P. H., Nagorny, C. L., Andersson, L. E., Nitert, M. D., Ridderstråle, M., Mulder, H., & Ling, C. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.422527 · Cited by 71
Hollingdal, M., Juhl, C. B., Dall, R., Sturis, J., Veldhuis, J. D., Schmitz, O., & Pørksen, N. (2002) · Diabetologia · doi:10.1007/s125-002-8244-y · Cited by 67
Physiological consequences of phasic insulin release in the normal animal
Cherrington, A. D., Sindelar, D., Edgerton, D., Steiner, K., & McGuinness, O. P. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s103 · Cited by 63
Larsson, H., & Ahr�n, B. (1996) · Diabetologia · doi:10.1007/s001250050559 · Cited by 60
Ritzel, R. A., Veldhuis, J. D., & Butler, P. C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021250 · Cited by 56
Characteristics and Prevalence of Latent Autoimmune Diabetes in Adults (LADA)
Brahmkshatriya, P. P., Mehta, A. A., Saboo, B. D., & Goyal, R. K. (2012) · ISRN Pharmacology · doi:10.5402/2012/580202 · Cited by 54
Knowles, N. G., Landchild, M. A., Fujimoto, W. Y., & Kahn, S. E. (2002) · Diabetes Care · doi:10.2337/diacare.25.2.292 · Cited by 51
“The change in -cell function has been demonstrated to include a reduction in insulin secretion in response to glucose (2).”
BackgroundIslet dysfunction in obese women with impaired glucose tolerance
Larsson, H., & Ahrén, B. (1996) · Metabolism · doi:10.1016/s0026-0495(96)90227-9 · Cited by 44
Glucose Metabolism in Older Adults: A Study Including Subjects More Than 80 Years of Age
Garcia, G. V., Freeman, R. V., Supiano, M. A., Smith, M. J., Galecki, A. T., & Halter, J. B. (1997) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1997.tb01507.x · Cited by 35
Mulder, H., Ahrén, B., & Sundler, F. (1996) · Diabetologia · doi:10.1007/bf00418536 · Cited by 31
“Fully developed NIDDM is characterized by impaired insulin secretion in combination with reduced peripheral insulin sensitivity [8, 9].”
BackgroundPioglitazone prevents reactive hypoglycemia in impaired glucose tolerance
Arii, K., Ota, K., Suehiro, T., Ikeda, Y., Nishimura, K., Kumon, Y., & Hashimoto, K. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.01.004 · Cited by 15
Metadata
- Authors
- Porte, D.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1991-02-01
- Volume
- 40
- Issue
- 2
- Pages
- 166-180
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2129754316
- Cited by
- 585
- References
- 0
- FWCI
- 20.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.